Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 17/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5193904 | 0.99 | ADRB3 (0.65) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL5193899 | 0.99 | ADRB3 (0.65) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| SCHEMBL1120838 | 0.93 | ADRB3 (0.65) | ADRB3ADRA1A | |
| SCHEMBL1120839 | 0.93 | ADRB3 (0.65) | ADRB3ADRA1A | |
| Hydrochloric Acid SCHEMBL5194384 | 0.92 | ADRB3 (0.64) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL5194392 | 0.92 | ADRB3 (0.64) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| SCHEMBL1120904 | 0.91 | ADRB3 (0.63) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| SCHEMBL1120888 | 0.91 | ADRB3 (0.63) | ADRB3ADRA1A | |
| SCHEMBL1120825 | 0.91 | ADRB3 (0.63) | ADRB3ADRA1A | |
| SCHEMBL5193807 | 0.91 | ADRB3 (0.71) | ADRB3ADRA1ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1277736-B1 | NOVEL BICYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2007-08-08 | — | — | EP | claimed |
| US-6861444-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-01 | — | — | US | claimed |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | ASAHI KASEI PHARMA CORPORATION (JP) | 2003-10-09 | — | — | US | claimed |
| EP-1277736-A1 | NOVEL BICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2003-01-22 | — | — | EP | claimed |
| EP-1277736-B1 | NOVEL BICYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-7049445-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-05-23 | — | — | US | disclosed |
| US-6861444-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-07-01 | — | — | US | disclosed |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | ASAHI KASEI PHARMA CORPORATION (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1277736-A1 | NOVEL BICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | GPR119, ADRB3, DBH | ADRB3 2/4885ADRA1A 44/4885DRD2 263/4885 |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | GPR119, GIPR, SLC5A2 | ADRB3 953/4885ADRA1A 1421/4885DRD2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.